News and Events

Latest News

Stay up to date on Relief activities

Here you will find latest news, upcoming events and interviews.

Corporate News

Archive

Relief Therapeutics and InveniAI Sign a Strategic Collaboration Agreement to Identify New Product Development Opportunities using Artificial Intelligence

24 November 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Reports that its U.S. Collaboration Partner has Announced the U.S. Food and Drug Administration has Denied Breakthrough Designation for Aviptadil

24 November 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Launches Level 1 ADR Program in the United States

18 November 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Reports that its U.S. Collaboration Partner has Announced it has Received a U.S. Food and Drug Administration Review of Aviptadil Manufacturing Information

12 November 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Provides Corporate Update and Outlines Plans to Advance its Diversified Portfolio of Pipeline Candidates, Including RLF-100™ (Aviptadil)

11 November 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces Transitions in Commercial Organization to Implement Next Phase of Corporate Development

09 November 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Reports that its U.S. Collaboration Partner’s Emergency Use Authorization Request for ZYESAMI®/RLF-100™ (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure was Declined by the U.S. Food & Drug Administration

05 November 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Takes First Step to Create an ADR Program in the United States by filing a Form F-6 Registration Statement with the U.S. Securities and Exchange Commission

03 November 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Reports that its U.S. Collaboration Partner has Announced a Favorable, New Safety Report for Aviptadil in the National Institutes of Health Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19

03 November 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics’ Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Positive Interim Data from Its Clinical Trial of Novel Nasal Spray Sentinox in SARS-CoV-2 Infected Patients

27 October 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Events and Presentations

H.C. Wainwright 23rd Annual Global Investment Conference - September 13 - 15, 2021

Monday, September 13, 2021

7:00am EST

Listen to Webcast

Download the Presentation

Scientific References

RLF-100™

Media Contact

For media inquiries contact:

Rx Communication Group
Michael Miller
Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel.: 917.633.6086

Latest News

Corporate News

Archive

Relief Therapeutics and InveniAI Sign a Strategic Collaboration Agreement to Identify New Product Development Opportunities using Artificial Intelligence

Relief Reports that its U.S. Collaboration Partner has Announced the U.S. Food and Drug Administration has Denied Breakthrough Designation for Aviptadil

Relief Therapeutics Launches Level 1 ADR Program in the United States

Relief Reports that its U.S. Collaboration Partner has Announced it has Received a U.S. Food and Drug Administration Review of Aviptadil Manufacturing Information

Relief Provides Corporate Update and Outlines Plans to Advance its Diversified Portfolio of Pipeline Candidates, Including RLF-100™ (Aviptadil)

Relief Therapeutics Announces Transitions in Commercial Organization to Implement Next Phase of Corporate Development

Relief Reports that its U.S. Collaboration Partner’s Emergency Use Authorization Request for ZYESAMI®/RLF-100™ (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure was Declined by the U.S. Food & Drug Administration

Relief Therapeutics Takes First Step to Create an ADR Program in the United States by filing a Form F-6 Registration Statement with the U.S. Securities and Exchange Commission

Relief Reports that its U.S. Collaboration Partner has Announced a Favorable, New Safety Report for Aviptadil in the National Institutes of Health Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19

Relief Therapeutics’ Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Positive Interim Data from Its Clinical Trial of Novel Nasal Spray Sentinox in SARS-CoV-2 Infected Patients

Events and Presentations

H.C. Wainwright 23rd Annual Global Investment Conference - September 13 - 15, 2021

Scientific References

RLF-100™

Media Contact

Company

Pipeline

Investor Relations

News and Events